Serveur d'exploration Tocilizumab - Curation (PubMed)

Index « Auteurs » - entrée « Keisuke Izumi »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Keisuke Ishizawa < Keisuke Izumi < Keisuke Kawamoto  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 6.
Ident.Authors (with country if any)Title
000623 (2019) Michitaro Hayakawa [Japon] ; Keisuke Izumi [Japon] ; Misako Higashida-Konishi [Japon] ; Mari Ushikubo [Japon] ; Masako Tsukamoto [Japon] ; Kumiko Akiya [Japon] ; Kazuhiro Araki [Japon] ; Hisaji Oshima [Japon]Tocilizumab-induced psoriasis-like eruption resolved by shortening the dose interval in a patient with rheumatoid arthritis: a case-based review.
000B99 (2017) Shuntaro Saito [Japon] ; Yuko Kaneko [Japon] ; Keisuke Izumi [Japon] ; Tsutomu Takeuchi [Japon]Utility of Dose Frequency Adjustment in Tocilizumab Administration for Rheumatoid Arthritis.
000F12 (2016) Keisuke Izumi ; Yuko Kaneko ; Misato Hashizume ; Keiko Yoshimoto ; Tsutomu TakeuchiCorrection: Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).
000F92 (2015) Keisuke Izumi [Japon] ; Yuko Kaneko [Japon] ; Misato Hashizume [Japon] ; Keiko Yoshimoto [Japon] ; Tsutomu Takeuchi [Japon]Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).
001002 (2015) Keisuke Izumi [Japon] ; Harumi Kuda [Japon] ; Mari Ushikubo [Japon] ; Masataka Kuwana [Japon] ; Tsutomu Takeuchi [Japon] ; Hisaji Oshima [Japon]Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable cases.
001446 (2015) Keisuke Izumi [Japon] ; Yuko Kaneko ; Hidekata Yasuoka ; Noriyuki Seta ; Hideto Kameda ; Masataka Kuwana ; Tsutomu TakeuchiTocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/PubMed/Curation
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/Author.i -k "Keisuke Izumi" 
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/Author.i  \
                -Sk "Keisuke Izumi" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    PubMed
   |étape=   Curation
   |type=    indexItem
   |index=    Author.i
   |clé=    Keisuke Izumi
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021